Kura Oncology, Inc. KURA
We are a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Since our founding in 2014, we have transformed from a research and development company to a fully-integrated commercial-stage organization with a diversified pipeline of product candidates. Our pipeline consists of small molecules designed to target cancer signaling pathways and address significant unmet needs in oncology and hematology.
2025 was a pivotal year for our company. On November 13, 2025, the FDA approved our new drug application, or NDA, for ziftomenib, which is being marketed in the United States under the trade name KOMZIFTITM, for the treatment of adults with relapsed or refractory acute myeloid leukemia, or AML, with a susceptible nucleophosmin 1, or NPM1, mutation who have no satisfactory alternative treatment options. KOMZIFTI is the first and only menin inhibitor approved by the FDA for once-daily oral administration.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0 | — | — | — | — | — | — | — |
| R&D | $251.1M | $170.0M | $115.2M | $92.8M | $84.7M | $60.4M | $47.8M | $46.8M | $26.4M | — |
| SG&A | $120.0M | $77.1M | $50.6M | $47.1M | $46.5M | $31.5M | $19.7M | $16.1M | $9.7M | — |
| Total operating expenses | $371.1M | $247.1M | $165.8M | $139.9M | $131.3M | $91.9M | $67.5M | $62.9M | $36.1M | $28.4M |
| Operating income | -$303.6M | -$193.2M | -$165.8M | -$139.9M | — | — | — | — | — | — |
| Interest expense | $1.5M | $1.6M | $1.5M | $229.0K | $414.0K | $578.0K | $580.0K | $970.0K | $888.0K | $577.0K |
| Pre-tax income | -$278.4M | -$172.0M | -$152.6M | -$135.8M | -$130.5M | -$89.6M | -$63.1M | -$60.4M | -$35.4M | -$27.6M |
| Income tax | $297.0K | $2.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$278.7M | -$174.0M | -$152.6M | -$135.8M | -$130.5M | -$89.6M | -$63.1M | -$60.4M | -$35.4M | -$27.6M |
| EPS, basic | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | — | — | — | — |
| EPS, diluted | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 | -1.72 | -1.52 | -1.47 |
| Shares, diluted (wtd. avg.) | $87.7M | $86.2M | $73.2M | $67.0M | $66.4M | $53.1M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $149.1M | $224.5M | $37.3M | $51.8M | $90.7M | $325.5M | $26.1M | $16.1M | $11.4M | $9.7M |
| Short-term investments | $518.1M | $502.9M | $386.6M | $386.2M | $427.3M | $307.8M | $210.8M | $162.9M | $81.7M | — |
| Receivables | $8.8M | $2.1M | — | — | — | — | — | — | — | — |
| Inventory | $413.0K | $0 | — | — | — | — | — | — | — | — |
| Total current assets | $708.7M | $744.8M | $432.5M | $446.4M | $522.3M | $637.3M | $239.6M | $181.2M | $94.6M | $68.8M |
| Property, plant and equipment | $7.9M | $1.7M | $1.9M | $2.5M | $2.7M | $2.0M | $44.0K | — | $10.0K | $40.0K |
| Total assets | $738.4M | $760.2M | $448.9M | $456.3M | $534.1M | $647.2M | $242.0M | $182.4M | $95.9M | $69.8M |
| Accounts payable | $5.0M | $1.5M | $2.3M | $1.5M | $3.2M | $2.8M | $3.5M | $3.9M | $1.2M | $638.0K |
| Short-term debt | $0 | $2.6M | — | — | — | $3.0M | $250.0K | — | $1.5M | — |
| Total current liabilities | $117.0M | $78.7M | $35.3M | $24.1M | $22.5M | $26.0M | $15.6M | $13.6M | $10.0M | $5.5M |
| Long-term debt | $9.7M | $6.9M | $9.3M | $9.2M | — | $4.2M | $7.2M | $7.5M | $5.6M | $7.3M |
| Total liabilities | $564.2M | $346.5M | $51.7M | $36.0M | $27.4M | $36.3M | $23.2M | $21.4M | $16.0M | $12.9M |
| Retained earnings | -$1.17B | -$895.4M | -$721.4M | -$568.8M | -$433.0M | -$302.5M | -$212.9M | -$149.7M | -$89.3M | -$53.9M |
| Total equity | $174.1M | $413.6M | $397.3M | $420.3M | $506.6M | $610.9M | $218.8M | $161.0M | $79.9M | $56.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$64.1M | $134.3M | -$124.8M | -$110.1M | -$104.6M | -$69.8M | -$54.8M | -$48.7M | -$28.4M | -$25.3M |
| Depreciation and amortisation | $1.0M | $848.0K | $849.0K | $759.0K | $558.0K | $194.0K | $0 | $10.0K | $30.0K | $31.0K |
| Stock-based compensation | $37.1M | $33.9M | $28.1M | $26.3M | $23.6M | $12.8M | $9.4M | $8.7M | $4.5M | $2.1M |
| Capital expenditure | $6.6M | $472.0K | $168.0K | $626.0K | $1.1M | $2.2M | — | — | — | — |
| Investing cash flow | -$13.1M | -$101.6M | $15.6M | $32.6M | -$126.8M | -$99.9M | -$46.3M | -$79.3M | -$23.4M | $12.2M |
| Financing cash flow | $1.8M | $154.4M | $94.8M | $38.6M | -$3.4M | $469.3M | $111.1M | $132.6M | $53.6M | $7.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-151335.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |